Equities Analysts Set Expectations for RDY Q4 Earnings

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Equities research analysts at Zacks Research lifted their Q4 2026 earnings per share (EPS) estimates for shares of Dr. Reddy’s Laboratories in a report issued on Monday, March 17th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.20 for the quarter, up from their prior forecast of $0.19. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $0.80 per share.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%.

RDY has been the subject of a number of other research reports. Nomura downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th. StockNews.com lowered Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th.

Dr. Reddy’s Laboratories Stock Up 1.1 %

Shares of Dr. Reddy’s Laboratories stock opened at $13.73 on Thursday. Dr. Reddy’s Laboratories has a 1 year low of $12.50 and a 1 year high of $16.89. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. The company has a 50-day moving average of $13.66 and a 200 day moving average of $14.71. The firm has a market cap of $11.46 billion, a price-to-earnings ratio of 21.86 and a beta of 0.48.

Institutional Trading of Dr. Reddy’s Laboratories

Institutional investors have recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. raised its holdings in Dr. Reddy’s Laboratories by 453.8% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock worth $180,620,000 after buying an additional 9,373,412 shares during the last quarter. Royal Bank of Canada raised its holdings in Dr. Reddy’s Laboratories by 403.1% in the 4th quarter. Royal Bank of Canada now owns 10,037,246 shares of the company’s stock worth $158,489,000 after acquiring an additional 8,042,163 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Dr. Reddy’s Laboratories by 382.9% in the 4th quarter. Renaissance Technologies LLC now owns 9,418,428 shares of the company’s stock worth $148,717,000 after acquiring an additional 7,467,979 shares during the last quarter. Aikya Investment Management Ltd lifted its position in Dr. Reddy’s Laboratories by 416.1% in the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company’s stock valued at $88,590,000 after acquiring an additional 4,523,303 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Dr. Reddy’s Laboratories by 405.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 5,361,013 shares of the company’s stock valued at $84,643,000 after purchasing an additional 4,301,212 shares during the last quarter. 3.85% of the stock is owned by hedge funds and other institutional investors.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.